NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
Telatinib Demonstrates Positive Results in First-Line Treatment
Barret’s Less of a Risk Factor For Cancer of the Esophagus
New Abiraterone Acetate Results Show Greater Benefit Than Before
MGMT Gene Can Determine Disease Aggressiveness
Phase III Study: Lymphoseek Superior to Vital Blue Dye
Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
Smokers Quitlines Found Effective Regardless of Recruitment Method
Study: Vismodegib Effective Where Surgery is Inappropriate
NCI-Approved Clinical Trials For The Month of June
FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- Makary: Level of evidence is an artificial and dogmatic construct
- The other side of the patient portal: Reflections from a cancer center leader
- Surviving cancer is often not a patient’s most challenging battle